NCT01995604

Brief Summary

The purpose of this study is to evaluate the efficacy of dHACM (Dehydrated Human Amnion Chorion Membrane) for reducing time to healing when used in post-laser recovery following ActiveFX™ and DeepFx™ fractionated ablative CO2 laser resurfacing of the face.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Sep 2013

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2013

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2013

Completed
20 days until next milestone

First Submitted

Initial submission to the registry

November 21, 2013

Completed
5 days until next milestone

First Posted

Study publicly available on registry

November 26, 2013

Completed
5 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
Last Updated

June 13, 2014

Status Verified

June 1, 2014

Enrollment Period

2 months

First QC Date

November 21, 2013

Last Update Submit

June 12, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • The time to healing for both groups will be assessed as defined by appearance and 100% epithelialization.

    Day 30

Secondary Outcomes (1)

  • Erythema, edema, crusting, and exudate will be compared between both groups.

    30 Days

Other Outcomes (1)

  • Pain Reduction

    30 Days

Study Arms (2)

dHACM

EXPERIMENTAL

UltraPulse laser therapy with application of dHACM

Other: Application of dHACM

Sterile 0.9% Saline Solution

PLACEBO COMPARATOR

UltraPulse laser therapy with application of Sterile 0.9% Saline Solution

Other: Application of Sterile 0.9% Saline Solution

Interventions

Application of Sterile 0.9% Saline Solution to half of face after UltraPulse laser therapy.

Sterile 0.9% Saline Solution

Application of dHACM to half of face after UltraPulse laser therapy.

dHACM

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female subjects in good general health greater than 18 years of age
  • Must be willing to agree to all terms of the protocol and provide a completed and signed informed consent, HIPAA and photography release forms
  • Subjects planning to undergo fractionated ablative CO2 laser resurfacing to the full face
  • Subject of either Fitzpatrick Skin Types I, II or III
  • For female subjects of childbearing potential, they must have had a regular menstrual cycle prior to study entry and is willing to use an acceptable form of birth control during the entire course of the study. All systemic birth control measures must be in consistent use at least 30 days prior to entry into the study. A female is considered NOT to be of childbearing potential if she is postmenopausal for at least one (1) year, without a uterus and/or both ovaries, or has had a bilateral tubal ligation. Acceptable methods of birth control are: oral contraceptives, contraceptive patches/rings/implants Norplant, Depo-Provera, double-barrier methods (e.g. condoms and spermicide), abstinence and vasectomies of the partner.
  • Negative urine pregnancy test results at the time of study entry for females of childbearing potential, if applicable
  • Must be willing to comply with study instructions and complete the entire course of the study

You may not qualify if:

  • Any uncontrolled systemic disease that is not yet stabilized for at least one (1) year
  • A significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would interfere with the objectives of the study
  • Recently excessive exposure to sunlight or artificial UV light (e.g.: use of tanning beds/booths and/or sunbathing) or expectations of tanning during the time of the study or has used self-tanner within 7 days of study entry
  • History of or the presence of any skin condition/disease that might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis, seborrheic dermatitis)
  • Active bacterial, fungal, or viral infection
  • History of Herpes Simplex Virus to the facial and/or perioral areas
  • Known allergies or sensitivities to benzocaine, lidocaine, tetracaine, PABA (para-aminobenzoic acid), or other local anesthetics of the amide or ester family
  • Known allergies to gentamicin and/or streptomycin
  • Receiving any topical products containing alpha-hydroxy acids, salicylic acid, and Vitamins C or E (including derivatives of Vitamins C or E) on the face within 14 days prior to or during the study period, other than the ingredients of the study products
  • Receiving and/or has had a microdermabrasion (light or medium skin peel) treatment on their face within 30 days prior to or during the study period
  • Using any topical tretinoin product or derivative on their face within 12 weeks prior to or during the study period
  • Receiving a chemical peel, any systemic steroids, a non-ablative laser, light or radio frequency treatment and/or has had a Dermabrasion (deep skin peel) or ablative laser treatments on their face must have discontinued the drug/treatment and/or had the procedure at least 3 months prior to entering the study
  • History of keloids or hypertrophic scars
  • Use of systemic retinoids, prescription or over-the-counter grade within the past year
  • A female subject who is pregnant, nursing an infant or planning a pregnancy during the study
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dermatology Cosmetic Laser Medical Associates of LaJolla, Inc.

San Diego, California, 92121, United States

Location

MeSH Terms

Conditions

Cicatrix

Interventions

Saline Solution

Condition Hierarchy (Ancestors)

FibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Crystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Officials

  • Mitchel P Goldman, MD

    Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc.

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 21, 2013

First Posted

November 26, 2013

Study Start

September 1, 2013

Primary Completion

November 1, 2013

Study Completion

December 1, 2013

Last Updated

June 13, 2014

Record last verified: 2014-06

Locations